How long should you stay on weight loss injections?

You've reached a stable weight, now what?

Picture this: you started your injection six months ago, you have lost a significant amount of weight, your clothes fit differently, and your GP has noticed an improvement in your blood pressure. The instinct to stop (to declare the job done) is completely understandable. The difficulty is that weight loss injections like tirzepatide (Mounjaro) and semaglutide (Wegovy) do not cure obesity; they manage it, in much the same way that blood-pressure medication manages hypertension. Once the medicine leaves your system, the hormonal signals that were suppressing appetite return. Studies consistently show that most people regain a substantial proportion of lost weight within a year of stopping, without additional support in place.

That does not mean you must stay on them indefinitely, but it does mean the decision to stop should be planned rather than impulsive. A good time to have that conversation with your prescriber is when your weight has been stable for several months and you have built sustainable eating and activity habits alongside treatment, and if you are thinking carefully about how long you should be on weight loss injections, that question is worth working through with your clinician before making any changes. The medicine can help you establish those habits; it cannot install them on its own.

If you are weighing up whether injections are the right route for you at all, the broader question of whether weight loss injections suit your situation is worth reading first.

What UK guidance sets as the framework

NICE's recommendation for semaglutide (Wegovy) under NICE technology appraisal TA875 specifies a maximum of two years of treatment within a specialist NHS weight management service, and advises reviewing continuation if less than five percent of body weight is lost after six months on the maintenance dose. That two-year cap applies to the NHS pathway, not to private prescribing, where clinical judgement governs.

For tirzepatide (Mounjaro), NICE's appraisal TA1026 does not set a fixed maximum duration in the same way. The prescriber reviews whether the benefit continues to justify ongoing treatment, particularly if progress has plateaued. The NHS England guidance on weight management injections frames these medicines as long-term tools, not short courses, and emphasises wraparound diet and activity support throughout.

In private practice, many clinicians take a similar long-term view, and understanding how long you can stay on weight loss injections helps set realistic expectations about what ongoing treatment involves. Some people treat for 18 months and then taper with prescriber support; others stay on a maintenance dose for several years. Both can be appropriate.

If the cost of longer-term treatment is a factor you are thinking through, the full picture on what weight loss injection pricing covers explains what private prescriptions typically include and what to watch for.

The risks of stopping too soon, and how to stop safely if the time is right

Stopping abruptly, especially before weight-related health conditions have fully stabilised, carries a measurable risk. The appetite-suppressing effect fades within days to weeks of the last dose. Without that physiological support, hunger signals often return more strongly than patients expect, and the habits built during treatment are tested harder.

A safer approach, if you and your prescriber agree the time is right, is a gradual step-down rather than an abrupt stop, and reading about how long you should take weight loss injections can help frame that conversation before you meet with your clinician. This is not always straightforward, because some people find lower doses less tolerable than the dose they have settled on, but it is worth discussing.

It is also worth being honest with yourself about timing. If you are planning to stop around a particularly disruptive period (a holiday, a house move, a run of stressful months) your prescriber may suggest holding steady a little longer. Equally, if you order on a monthly basis and life events shift the routine (a bank holiday, a payday delay), that is worth flagging when you get in touch with our support team rather than simply missing a dose.

The most common questions our patients ask about ongoing treatment include exactly this, how to handle gaps, what to do if a dose is delayed, and when to flag a change in how the medicine is working. Your prescriber and the Patient Information Leaflet are the right references for your specific situation.

Long-term safety: what we know so far

Both tirzepatide and semaglutide are relatively new medicines in the weight management setting, and both carry a Black Triangle (▼) designation, meaning the MHRA collects additional data on their long-term safety as use widens. That does not mean they are unsafe; it means the evidence base is actively growing. The clinical trials that supported their licensing (SURMOUNT-1 for tirzepatide and STEP 1 for semaglutide, each running for over a year) did not identify new safety signals that would cap duration, but longer real-world data continue to accumulate.

What is clear from the NHS patient information for tirzepatide and equivalent semaglutide guidance is that ongoing prescribing should be supervised. Side effects, any new diagnoses, and changes to other medicines all need to be factored in at each review. That is precisely why every repeat at nume goes through a fresh clinical assessment before anything is dispatched, not because the rules require it, but because it is the only safe way to run long-term treatment.

If you would like to talk through your situation and whether continuing, pausing or stopping makes sense for you, our prescribers are available seven days a week. Check your eligibility and start a free consultation, there is no obligation, and the conversation is the right place to begin.